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Mouse monoclonal antibody MON-100 was raised against the neuroendocrine protein 7B2 using bacterially produced 
hybrid proteins. In Western blot analysis, MON-100 reacted with 3 different 7B2 hybrid proteins and not with the respec- 
tive carrier proteins. Furthermore, MON-100 was reactive with recombinant 7B2 cleaved from a hybrid protein. In an 
immunohistochemical study, MON-100 exhibited strong reactivity with the intermediate lobe of the Xenopus pituitary 
gland, a tissue previously shown to contain 7B2 mRNA. Using MON-100, immunoprecipitation analysis of newly synthe- 
sixed proteins produced by in vitro incubated Xenopur neurointennediate lobes revealed the biosynthesis of a single prot- 
ein of M, 24 kDa, the expected size of the 7B2 protein. It appears, therefore, that the anti-7B2 monoclonal antibody 
MON-100 can be successfully used for Western blot analysis and immunohistochemical nalysis as well as for immuno- 
precipitation experiments. 
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1. INTRODUCTION 
7B2 is a nonglycosylated neuroendocrine 
polypeptide consisting of approximately 180 
amino acids [l] and intracellularly compartmen- 
talized within secretory granules [2]. This 
19-24 kDa protein [3-51, originally isolated from 
porcine anterior pituitary glands [l], is widely 
distributed within the central nervous system [5] as 
well as in endocrine tissues and tumors [6-B]; 7B2 
may be a plasma marker for endocrine tumors [6]. 
Recently we showed that the 7B2 protein is highly 
conserved during 350 million years of vertebrate 
evolution [9]. The physiological function of the 
7B2 protein is yet unknown. It has been proposed 
that 7B2 could be a growth factor [lo], a hormone, 
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a neurotransmitter/neuromodulator [1 l] or it 
could be a factor regulating some intracellular 
function [ 121. The fact that 7B2 is an unstable pro- 
tein [13] and that it is present in neural and en- 
docrine tissues in only minute amounts [6,10] 
hampers functional studies of this interesting 
neuroendocrine protein. We applied recombinant 
DNA technology and bacterial expression vectors 
to produce relatively large amounts of recombi- 
nant human 7B2 protein. Using the recombinant 
7B2 protein it was possible to develop anti-7B2 
monoclonal antibodies. The availability of the 
recombinant protein and the monoclonal antibody 
will allow us to perform studies aimed at 
elucidating the function of 7B2. 
2. MATERIALS AND METHODS 
2.1. Preparation of hybrid proteins 
Using standard recombinant DNA techniques [14], 3 hybrid 
proteins were obtained consisting of human 7B2 [15] linked to 
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fl-galactosidase (,&gal), to anthranilate-synthetase (AS) or to 
worm glutamylcysteinylglycine-binding protein @BP). The 
GBP-7B2 hybrid protein was purified with affinity 
chromatography using glutamylcysteinylglycine-agarose 
(Sigma). The purified hybrid protein GBP-7B2 was treated with 
the site-specific serine protease thrombin, resulting in the pro- 
duction of intact GBP and 7B2; the consensus equence for this 
cleavage is: P4-P3-Pro-Arg-Pl-P2, where P3 and P4 are 
hydrophobic amino acids and Pl and P2 are nonacidic amino 
acids [ 161. 
2.2. Development of monoclonal antibodies directed against 
782 
Female Balb/c mice, 2-3 months old, were used for in- 
traperitoneal (i.p.) immunization with 5Ogg of recombinant 
hybrid protein in complete Freund’s adjuvant. After 4 weeks, 
the mice were rechallenged i.p. using incomplete Freund’s adju- 
vant. Ten days after the last injection, a final dose of 25 ,ug of 
protein was given intravenously (i.v.) and 3 days later the spleen 
was removed. 
The first fusion experiment was performed after 4 
rechallenges using complete bacterial ysate containing AS-7B2. 
For the second fusion experiment, amouse was immunized with 
partly purified GBP-7B2 and one rechallenge was sufficient to 
raise an immune response against 7B2. Fusions were performed 
according to the polyethylene glycol (PEG) procedure of Lane 
[17], using Spz/O-Ag14 myeloma cells [18] as a fusion partner, 
except that PEG (Kodak) was diluted in RPM1 1640 instead of 
dimethylsulfoxide and phosphate-buffered saline. No feeder 
macrophages were used. By this procedure, up to 20000 clones 
can be generated in each fusion. 
Antibodies produced by hybridomas generated in the first fu- 
sion were analyzed using a rapid immunoblot screening techni- 
que [19]. As a first screening assay for the second fusion 
experiment, an ELISA was developed. Culture supernatant of 
each clone was tested for reactivity with complete bacterial 
lysates containing AS-7B2, GBP or GBP-7B2, coated to 
microtiter dishes (Costar). Positive hybridoma cultures were 
subsequently cloned three times by the limiting dilution 
method. Cultures of hybridomas were maintained in RPM1 
1640 supplemented with streptomycin (100 pg/ml), penicillin 
(100 U/ml), 2 mM L-glutamine and 10% fetal bovine serum 
(High Clone). 
2,3. Protein analysis 
Protein samples were analyzed using 12.5% SDS- 
polyacrylamide gel electrophoresis (PAGE) [20], elec- 
trotransferred onto nitrocellulose [21] and tested for im- 
munoreactivity with antisera essentially as described by Mulders 
et al. [22]. Neurointermediate lobe cells of South African claw- 
ed toads, Xenopus laevb, were labeled according to Martens et 
al. [23] for 15 min with [3H]lysine and [‘Hlproline, and subse- 
quent immunoprecipitation was performed according to Dep- 
pert and Haug [24]. Toads were kept in black buckets under 
constant illumination for at least 3 weeks. 
2.4. Immunocytochemistry 
Xenopus brain and pituitary were fiied in Bouin-Hollande, 
Paraplast-embedded, and 5 ,um sections were immunostained 
using the peroxidase anti-peroxidase method according to 
Sternberger [25] using diaminobenzidine as oxygen acceptor 
and ammonium nickel sulphate enhancement. As a control, 
non-immune mouse serum was applied. 
3. RESULTS AND DISCUSSION 
The major objective of this study was to isolate 
relatively large amounts of the 7B2 protein in order 
to develop 7BZspecific monoclonal antibodies. 
The availability of the recombinant protein and the 
antibody might enable us to study the neuroen- 
docrine protein’ 7B2 more extensively and these 
products might be instrumental to elucidate the 
unknown function of 7B2. Since only a limited 
amount of 7B2 is present in tissues [lo], bacterial 
expression of 7B2 might constitute a valuable alter- 
native approach to obtain relatively large amounts 
of this small non-glycosylated protein. We here 
report that 7B2 can indeed be produced in large 
quantities as part of stable hybrid proteins (fig. lA, 
lanes 2, 4 and 6); we have been unsuccessful to 
bacterially produce the 7B2 protein itself (G.J.M. 
Martens and P.J.T.A. Groenen, unpublished). In- 
jection of rabbits and mice with hybrid protein 
raised a strong immune response. Failure to pro- 
duce polyclonal antisera in rabbits with small 
amounts of the native porcine 7B2 has been 
reported by others [lo]. This may be due to im- 
munological tolerance because of the highly con- 
served nature of 7B2. This problem was apparently 
not encountered when 7B2 hybrid proteins were 
used for immunization, possibly because conjuga- 
tion of 7B2 to a carrier protein (AS or GBP) might 
have made the recombinant protein more im- 
munogenic. 
Fusion experiments resulted in the isolation of 3 
hybridomas producing monoclonal antibodies 
with reactivity towards 7B2 on immunoblots and 
in ELISA analysis (data not shown). Of these 
monoclonal antibodies, MON-100 showed the 
strongest reactivity with the 7B2 protein moiety of 
each of the hybrid proteins. As shown in fig.lB, 
the MON-100 antibody recognizes B-gal-7B2 
(136 kDa) (lane 2), AS-7B2 (57 kDa) (lane 4) and 
GBP-7B2 (46 kDa) (lane 6), and does not react 
with &gal (116 kDa) (lane l), AS (37 kDa) (lane 3) 
or GBP (29 kDa) (lane 5). Hence, this monoclonal 
antibody clearly has specificity for 7B2. To further 
establish that MON-100 recognizes an epitope 
within the 7B2 structure, the hybrid protein 
GBP-7B2 was cleaved with the site specific enzyme 
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Fig. 1. Analysis of 7B2 hybrid proteins. (A) Lysates of E. cofi expressing relatively large amounts of @-gal (116 kDa) (lane I), &gal-7B2 
(136 kDa) (lane 2), AS (37 kDa) (lane 3), AS-7B2 (57 kDa) (lane 4). GBP (29 kDa) (lane 5) and GBP-7B2 (46 kDa) (lane 6) were 
analyzed on SDS-PAGE. (B) Proteins, as in A, were electroblotted onto nitrocelhdose and this immunoblot was analyzed with the 
anti-7B2 monoclonal antibody MON-100. (C) Western blot showing the reactivity of MON-100 with partially thrombin-digested 
GBP-7B2. 
Fig.2. Immunoc~ochemical nalysis of Xenopus pituitary using anti-7B2 monoclonal antibody MON-IO0 (A) or normal mouse serum 
(B). AL, anterior lobe; IL, intermediate lobe; NL, neural lobe; ME, median eminence. 
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kDa M 1 2 3 As a final test for a possible application of 
MON-100, immunoprecipitation analysis of in 
vitro pulse labeled proteins produced by Xenopus 
neurointe~ediate lobes was performed. This 
analysis revealed a single protein of approximately 
24 kDa, while the normal mouse serum did not 
precipitate any protein, suggesting that this newly 
synthesized 24 kDa protein is 7B2. 
46- 
14- 
Fig.3. SDS-PAGE of immunoprecipitation a alysis of 3H- 
labeled proteins produced by Xenopus neurointermediate lobes 
(4 animals per lane) using normal mouse serum (lane 1) or 
anti-7B2 mono&o& antibody MON-1~ (lane 2). Lane 3: total 
extract of labeled proteins (equivalent to 0.2 lobe), M, 
molecular weight markers. 
thrombin and the cleavage products were subjected 
to Western blot analysis. As shown in fig.lC, 
MON-100 is reactive with the hybrid protein 
GBP-7B2 and intact 7B2; since GBP has no inter- 
nal thrombin cleavage sites, the minor im- 
munoreactive proteins of lower molecular weight 
represent 7B2 cleavage products. From fig. 1 it can 
be concluded that the epitope recognized by 
MON-100 resides within the 7B2 protein structure. 
To further evaluate the usefulness of MON-100, 
an immunocytochemical analysis of the pituitary 
gland of the toad Xerzopus, a tissue previously 
shown to contain 7B2 mRNA [9], was performed. 
Immunoreactivity for 7B2 was found in the three 
lobes of the Xenopus pituitary (fig.2), in line with 
the previously reported distribution of 7B2 in 
mouse and rat pituitary [5]. 
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We conclude’ that MON-100 recognizes 7B2 
specifically in all immunological techniques per- 
formed so far. This monoclonal antibody will be 
very useful in the elucidation of the biological 
function of the highly conserved neuroendocrine 
7B2 protein. 
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